(E)-2,5-dimethylhex-2-enoic acid | 99799-94-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-2,5-dimethylhex-2-enoic acid
• 英文别名: 2,5-dimethylhex-2-enoic acid；2,5-dimethyl-hex-2t-enoic acid；2,5-dimethyl-hex-2-enoic acid；2,5-Dimethyl-hex-2t-ensaeure；2,5-Dimethyl-hex-2-ensaeure
• CAS: 99799-94-7
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: BLCHIKLQYBVYAF-FNORWQNLSA-N

物化性质

• 沸点：
  235.5±9.0 °C(Predicted)
• 密度：
  0.954±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-2,5-dimethylhex-2-enoic acid 在 溴 作用下， 以 二氯甲烷 为溶剂， 生成 erythro-2,3-dibromo-2,5-dimethylhexanoic acid
  参考文献：
  名称：

  Synthesis of the Putative Structure of Tridachiahydropyrone

  摘要：

  A short total synthesis of the putative structure of the marine natural product tridachiahydropyrone as a single enantiomer is described. Novel steps include a cuprate addition and cyclization to form a cyclohexanone ring and formation of the bicyclic pyrone with P2O5 on Celite. The spectroscopic data obtained for compound 1 do not match those reported for tridachiahydropyrone; therefore, revision of the assigned natural product structure is warranted.

  DOI：

  10.1021/ol050236d
• 作为产物：
  描述：

  ethyl 2,5-dimethylhexa-2,4-dienoate2,5-dimethylsorbate 在 氢氧化钾 、 Pd-BaSO₄ 作用下， 生成 (E)-2,5-dimethylhex-2-enoic acid
  参考文献：
  名称：

  Inouye, Bulletin of the Institute for Chemical Research, Kyoto University, 1957, vol. 35, p. 49,70;

  摘要：

  DOI：

文献信息

• Asymmetric Hydrogenation of α,β-Unsaturated Carboxylic Acids Catalyzed by Ruthenium(II) Complexes of Spirobifluorene Diphosphine (SFDP) Ligands
  作者：Xu Cheng、Jian-Hua Xie、Sheng Li、Qi-Lin Zhou

  DOI：10.1002/adsc.200606065

  日期：2006.7

  The ruthenium diacetate complexes ligated by chiral spirobifluorene diphosphines (SFDP) were very effective catalysts for the asymmetric hydrogenation of tiglic acid derivatives and α-methylcinnamic acid derivatives with high activities and excellent enantioselectivities (up to 98 % ee). The α-aryloxybutenoic acids can also be hydrogenated by these catalysts to provide the corresponding saturated α-aryloxybutanoic

  由手性螺二芴二膦（SFDP）连接的二乙酸钌络合物是非常有效的催化剂，用于对酸衍生物和α-甲基肉桂酸衍生物进行不对称氢化，具有高活性和出色的对映选择性（最高98％ee）。这些催化剂还可以将α-芳氧基丁烯酸加氢，以提供相应的饱和α-芳氧基丁酸，以高收率（89-93％）和对映选择性（高达95％ee）提供。在该反应中，配体SFDP与对位上的甲基团P -苯基环，得到最好的结果。
• [EN] CARBIDOPA PRODRUGS AND USES THEREOF<br/>[FR] PROMEDICAMEMTS DE CARBIDOPA ET LEURS UTILISATIONS
  申请人：XENOPORT INC

  公开号：WO2004052841A1

  公开（公告）日：2004-06-24

  Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.

  卡比多巴的前药、卡比多巴前药的衍生物、卡比多巴及其衍生物前药的制作方法、卡比多巴及其衍生物前药的使用方法以及卡比多巴及其衍生物前药的组合物被公开。
• NANOSCALE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Sengupta Shiladitya

  公开号：US20120189571A1

  公开（公告）日：2012-07-26

  The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

  这项发明涉及生物相容性共轭聚合物纳米颗粒，包括一个共聚物骨架，多个共价连接到该骨架的侧链，以及多个可解离地连接到该骨架的铂化合物。该发明还涉及二羰基脂类化合物，其中铂化合物可可解离地连接到二羰基化合物。该发明还涉及治疗癌症或转移的方法。该方法包括选择需要癌症或转移治疗的受试者，并向受试者施用该发明的任何纳米颗粒、化合物或组合物的有效量。
• EUROPIUM COMPLEX
  申请人：TOSOH CORPORATION

  公开号：US20200354389A1

  公开（公告）日：2020-11-12

  To provide europium complexes having high photostability. A europium complex expressed with the following formula (A): wherein, R A and R B are independently a cyclic alkyl group with 3 to 10 carbons, respectively, and R C is a cyclic alkyl group with 3 to 10 carbons or a phenyl group expressed with the following formula (B): (wherein, X A , X B , A C , X D and X E independently represent a hydrogen atom; a fluorine atom; an alkyl group with 1 to 3 carbon(s); an alkyloxy group with 1 to 3 carbon(s); an aryloxy group with 6 to 10 carbons; a fluoroalkyl group with 1 to 3 carbon(s); a fluoroalkyloxy group with 1 to 3 carbon(s); or a phenyl group that may be substituted with a fluorine atom, an alkyl group with 1 to 3 carbon(s), an alkyloxy group with 1 to 3 carbon(s), a fluoroalkyl group with 1 to 3 carbon(s), a fluoroalkyloxy group with 1 to 3 carbon(s), a fluorophenyl group, a hydroxyl group or a cyano group, respectively); R A is a cyclic alkyl group with 3 to 10 carbons; R B and R C are a phenyl group expressed with the formula (B), provided, however, that a case where R A a cyclohexyl group, and, R B and R C are a phenyl group is excluded; or R A , R B and R C independently represent an ortho-substituted phenyl group expressed with the following formula (Ba): (wherein, X E represents a hydrogen atom, an alkyl group with 1 to 3 carbon(s), an alkyloxy group with 1 to 3 carbon(s), a fluoroalkyl group with 1 to 3 carbon(s), a fluoroalkyloxy group with 1 to 3 carbon(s), a naphthyl group that may be substituted with a fluorine atom, a pyridyl group that may be substituted with a fluorine atom, or a phenyl group that is expressed with a formula (C): [wherein, Z A , Z C and Z E independently represent a hydrogen atom, a fluorine atom, an alkyl group with 1 to 3 carbon(s), an alkyloxy group with 1 to 3 carbon(s), a fluoroalkyl group with 1 to 3 carbon(s), a fluoroalkyloxy group with 1 to 3 carbon(s), a phenyl group that may be substituted with a fluorine atom, a hydroxyl group or a cyano group; Z B and Z D independently represent a hydrogen atom or a fluorine atom, respectively], provided, however, that a case where R A , R B and R C are all a phenyl group is excluded), respectively; R D represents a hydrogen atom, a deuterium atom or a fluorine atom; W A and W B independently represent an alkyl group with 1 to 6 carbon(s), a fluoroalkyl group with 1 to 6 carbon(s), a phenyl group, a 2-thienyl group or a 3-thienyl group; and ‘n’ represents an integer of 1 to 3}.

  提供具有高光稳定性的铕配合物。 以下是用以下公式（A）表示的铕配合物： 其中，R A 和R B 分别独立地是具有3至10个碳原子的环烷基基团，而R C 是具有3至10个碳原子的环烷基基团或用以下公式（B）表示的苯基团： （其中，X A 、X B 、A C 、X D 和X E 独立地代表氢原子；氟原子；具有1至3个碳原子的烷基基团；具有1至3个碳原子的烷氧基团；具有6至10个碳原子的芳基氧基团；具有1至3个碳原子的氟烷基基团；具有1至3个碳原子的氟烷氧基团；或者可能被氟原子、具有1至3个碳原子的烷基基团、具有1至3个碳原子的烷氧基团、具有1至3个碳原子的氟烷基基团、具有1至3个碳原子的氟烷氧基团、氟苯基团、羟基或氰基取代的苯基团，分别）； R A 是具有3至10个碳原子的环烷基基团； R B 和R C 是用公式（B）表示的苯基团，但是，排除R A 为环己基团，且R B 和R C 为苯基团的情况；或者 R A ，R B 和R C 独立地表示用以下公式（Ba）表示的邻位取代的苯基团： （其中，X E 代表氢原子、具有1至3个碳原子的烷基基团、具有1至3个碳原子的烷氧基团、具有1至3个碳原子的氟烷基基团、具有1至3个碳原子的氟烷氧基团、可能被氟原子取代的萘基团、可能被氟原子取代的吡啶基团，或者用以下公式（C）表示的苯基团： [其中，Z A 、Z C 和Z E 独立地代表氢原子、氟原子、具有1至3个碳原子的烷基基团、具有1至3个碳原子的烷氧基团、具有1至3个碳原子的氟烷基基团、具有1至3个碳原子的氟烷氧基团、可能被氟原子取代的苯基团、羟基或氰基；Z B 和Z D 独立地代表氢原子或氟原子，但排除R A ，R B 和R C 都是苯基团的情况），分别；R D 代表氢原子、氘原子或氟原子；W A 和W B 独立地表示具有1至6个碳原子的烷基基团、具有1至6个碳原子的氟烷基基团、苯基、2-噻吩基团或3-噻吩基团；‘n’表示1至3的整数。
• Iridium-Catalyzed Enantioselective Hydrogenation of α,β-Unsaturated Carboxylic Acids
  作者：Shen Li、Shou-Fei Zhu、Can-Ming Zhang、Song Song、Qi-Lin Zhou

  DOI：10.1021/ja802399v

  日期：2008.7.1

  A highly efficient iridium-catalyzed hydrogenation of alpha,beta-unsaturated carboxylic acids has been developed by using chiral spiro-phosphino-oxazoline ligands, affording alpha-substituted chiral carboxylic acids in exceptionally high enantioselectivities and reactivities.

  已经通过使用手性螺-膦基-恶唑啉配体开发了一种高效的铱催化氢化 α,β-不饱和羧酸，从而以极高的对映选择性和反应性提供 α-取代的手性羧酸。